Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alnylam Pharmaceuticals, Inc.
  6. Summary
    ALNY   US02043Q1076

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
150.46(c) 151.08(c) 157.41(c) 163.26(c) 165.02(c) Last
847 124 470 538 653 503 655 329 709 347 Volume
+3.34% +0.41% +4.19% +3.72% +1.08% Change
More quotes
Financials (USD)
Sales 2021 833 M - -
Net income 2021 -750 M - -
Net cash position 2021 1 382 M - -
P/E ratio 2021 -25,9x
Yield 2021 -
Sales 2022 1 287 M - -
Net income 2022 -433 M - -
Net cash position 2022 1 170 M - -
P/E ratio 2022 -46,6x
Yield 2022 -
Capitalization 19 397 M 19 397 M -
EV / Sales 2021 21,6x
EV / Sales 2022 14,2x
Nbr of Employees 1 453
Free-Float 99,4%
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic... 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/15 | 10:00amPresentation
More about the company
Ratings of Alnylam Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ALNYLAM PHARMACEUTICALS, INC.
06/11INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Alnylam Phar..
MT
06/11Vertex Won't Move VX-864 into Late-Stage Testing After Disappointing Study Re..
MT
06/08ALNYLAM PHARMACEUTICALS  : Announces New Data from ATTR Amyloidosis Programs at ..
AQ
06/07ALNYLAM PHARMACEUTICALS  : Announces New Data from ATTR Amyloidosis Programs at ..
BU
06/01ALNYLAM PHARMACEUTICALS  : Completes Enrollment in Phase 3 Study of Patisiran
MT
06/01ALNYLAM PHARMACEUTICALS  : Completes Enrollment in APOLLO-B Phase 3 Study of Pat..
BU
05/26ALNYLAM PHARMACEUTICALS  : to Webcast Presentations at Upcoming June Investor Co..
BU
05/21ALNYLAM PHARMACEUTICALS, INC.  : Submission of Matters to a Vote of Security Hol..
AQ
05/13HEMOPHILIA A PIPELINE : Emerging Therapies and Key pharma players involved by De..
AQ
05/11ALNYLAM PHARMACEUTICALS  : Announces New Advances in ATTR Amyloidosis Program
BU
05/04ALNYLAM PHARMACEUTICALS  : Announces Positive Early Results on Clinical Outcome ..
AQ
05/04ALNYLAM PHARMACEUTICALS  : to Webcast Presentations at Upcoming May Investor Con..
BU
05/03ALNYLAM PHARMACEUTICALS  : Reports Positive Early Results in Phase 3 Study of Ox..
MT
05/03ALNYLAM PHARMACEUTICALS  : Announces Positive Early Results on Clinical Outcome ..
BU
04/29ALNYLAM PHARMACEUTICALS  : Q1 Adjusted Loss Grows
MT
More news
News in other languages on ALNYLAM PHARMACEUTICALS, INC.
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
2020NOVARTIS : feu vert européen à l'anticholestérol Leqvio
2020ALNYLAM PHARMACEUTICALS  : erhält EU-Zulassung für OXLUMO™ (Lumasiran) zur..
2020ALNYLAM PHARMACEUTICALS  : reçoit l'approbation de l'Union européenne pour OXLUM..
2020ALNYLAM PHARMACEUTICALS  : reçoit un avis positif du CHMP pour OXLUMO™ (lu..
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 172,60 $
Last Close Price 165,02 $
Spread / Highest target 42,4%
Spread / Average Target 4,59%
Spread / Lowest Target -44,9%
EPS Revisions
Managers and Directors
NameTitle
John M. Maraganore Chief Executive Officer & Director
Yvonne L. Greenstreet President & Chief Operating Officer
Jeffrey V. Poulton Chief Financial & Accounting Officer
Michael W. Bonney Chairman
Akshay K. Vaishnaw President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.26.97%19 397
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416